Complement C3 is a novel plasma clot component with anti-fibrinolytic properties
Complement C3 is a novel plasma clot component with anti-fibrinolytic properties
复制标题
补体 C3 是一种具有抗纤溶特性的新型血浆凝块成分
DOI：
--
复制
发表时间：
2012
影响因子：
2.4
通讯作者：
A. Carter
中科院分区：
文献类型：
--
作者：
Joanna‐Marie Howes;Victoria R. Richardson;Kerrie A. Smith;V. Schroeder;R. Somani;A. Shore;K. Hess;R. Ajjan;R. Pease;J. Keen;K. Standeven;A. Carter
Background and method: Increased plasma clot density and prolonged lysis times are associated with cardiovascular disease. In this study, we employed a functional proteomics approach to identify novel clot components which may influence clot phenotypes. Results: Analysis of perfused, solubilised plasma clots identified inflammatory proteins, including complement C3, as novel clot components. Analysis of paired plasma and serum samples confirmed concentration-dependent incorporation of C3 into clots. Surface plasmon resonance indicated high-affinity binding interactions between C3 and fibrinogen and fibrin. Turbidimetric clotting and lysis assays indicated C3 impaired fibrinolysis in a concentration-dependent manner, both in vitro and ex vivo. Conclusion: These data indicate functional interactions between complement C3 and fibrin leading to prolonged fibrinolysis. These interactions are physiologically relevant in the context of protection following injury and suggest a mechanistic link between increased plasma C3 concentration and acute cardiovascular thrombotic events.
